Green Cross Wellbeing Corporation announced that German regulatory authority, the Federal Institute for Drugs and Medical Devices (BfArM) has approved the company’s Clinical Trial Application (CTA) to advance BST204, a novel treatment for cancer cachexia, into a Phase 2 clinical trial in patient with cancer induced muscle loss, also known as cancer cachexia. Green Cross Wellbeing expects to initiate this study prior to the end of the first quarter 2018.